Intradermal vaccination, a promising solution for Mpox immunization
Mpox has been a persistent public health issue, particularly in the Democratic Republic of the Congo (DRC) and neighboring countries. The rising cases in the region, has caused mpox to be declared a public health emergency of international concern.
To address these challenges, the World Health Organization (WHO) has developed a strategic preparedness, readiness, and response plan for mpox. This plan includes enhancing surveillance, improving diagnostic capabilities, and conducting vaccination campaigns in affected areas.
Intradermal vaccination is thus particularly attractive for use in mass vaccination campaigns or outbreaks like now seen with Mpox. VAX-ID® can offer a solution in ease of use and standardization of the ID injection aiding in reliable ID administration by health care professionals.
Here are some quick facts about Mpox and our work in this space:
- Mpox was originally detected in monkeys BUT African rodents responsible for spread.
- Symptoms of mpox include fever, rash, swollen lymph nodes among others.
- DRC is the epicentre of Mpox clade I. Approximately 70% of mpox cases in DRC in 2024 were in CHILDREN under age 15.
- To address these challenges, the World Health Organization (WHO) has developed a strategic preparedness, readiness, and response plan for mpox.
- Vaccination is one key strategy to help prevent mpox outbreaks. Skin vaccination at 1/5th of the full dose can resolve supply constraints.
Want to know more. Read our full white paper here
